Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Stake Boosted by Chevy Chase Trust Holdings LLC

Chevy Chase Trust Holdings LLC increased its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGNGet Rating) by 5.6% during the third quarter, HoldingsChannel reports. The firm owned 280,344 shares of the biopharmaceutical company’s stock after acquiring an additional 14,881 shares during the period. Regeneron Pharmaceuticals accounts for approximately 0.8% of Chevy Chase Trust Holdings LLC’s holdings, making the stock its 19th biggest position. Chevy Chase Trust Holdings LLC’s holdings in Regeneron Pharmaceuticals were worth $193,122,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also recently bought and sold shares of the stock. Price T Rowe Associates Inc. MD grew its stake in Regeneron Pharmaceuticals by 92.5% during the 2nd quarter. Price T Rowe Associates Inc. MD now owns 1,694,308 shares of the biopharmaceutical company’s stock valued at $1,001,556,000 after acquiring an additional 813,967 shares in the last quarter. Renaissance Technologies LLC grew its stake in Regeneron Pharmaceuticals by 108.3% during the 2nd quarter. Renaissance Technologies LLC now owns 583,062 shares of the biopharmaceutical company’s stock valued at $344,665,000 after acquiring an additional 303,200 shares in the last quarter. FMR LLC grew its stake in Regeneron Pharmaceuticals by 1.9% during the 2nd quarter. FMR LLC now owns 10,176,199 shares of the biopharmaceutical company’s stock valued at $6,015,457,000 after acquiring an additional 193,175 shares in the last quarter. Great West Life Assurance Co. Can purchased a new position in Regeneron Pharmaceuticals during the 3rd quarter valued at about $116,414,000. Finally, Pendal Group Ltd grew its stake in Regeneron Pharmaceuticals by 5,221.0% during the 2nd quarter. Pendal Group Ltd now owns 158,779 shares of the biopharmaceutical company’s stock valued at $93,859,000 after acquiring an additional 155,795 shares in the last quarter. Hedge funds and other institutional investors own 84.25% of the company’s stock.

Regeneron Pharmaceuticals Stock Down 0.3 %

REGN opened at $727.47 on Wednesday. Regeneron Pharmaceuticals, Inc. has a twelve month low of $538.01 and a twelve month high of $779.00. The firm has a market cap of $79.22 billion, a P/E ratio of 15.34, a price-to-earnings-growth ratio of 2.17 and a beta of 0.22. The business has a 50 day moving average price of $732.22 and a 200 day moving average price of $690.27. The company has a debt-to-equity ratio of 0.13, a quick ratio of 4.52 and a current ratio of 5.36.

Regeneron Pharmaceuticals (NASDAQ:REGNGet Rating) last issued its quarterly earnings results on Thursday, November 3rd. The biopharmaceutical company reported $9.98 EPS for the quarter, topping analysts’ consensus estimates of $8.55 by $1.43. Regeneron Pharmaceuticals had a return on equity of 31.16% and a net margin of 39.17%. The company had revenue of $2.94 billion during the quarter, compared to analyst estimates of $2.79 billion. Research analysts forecast that Regeneron Pharmaceuticals, Inc. will post 38.45 EPS for the current year.

Insider Transactions at Regeneron Pharmaceuticals

In other news, EVP Marion Mccourt sold 1,000 shares of the company’s stock in a transaction that occurred on Friday, November 4th. The stock was sold at an average price of $727.82, for a total transaction of $727,820.00. Following the completion of the transaction, the executive vice president now directly owns 19,644 shares in the company, valued at $14,297,296.08. The sale was disclosed in a filing with the SEC, which can be accessed through this link. In related news, EVP Marion Mccourt sold 1,000 shares of the company’s stock in a transaction on Friday, November 4th. The stock was sold at an average price of $727.82, for a total value of $727,820.00. Following the completion of the transaction, the executive vice president now directly owns 19,644 shares in the company, valued at $14,297,296.08. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director N Anthony Coles sold 5,758 shares of the company’s stock in a transaction on Wednesday, December 28th. The shares were sold at an average price of $714.11, for a total value of $4,111,845.38. Following the completion of the transaction, the director now owns 1,093 shares of the company’s stock, valued at $780,522.23. The disclosure for this sale can be found here. Insiders sold a total of 19,212 shares of company stock worth $14,070,511 over the last three months. 8.99% of the stock is currently owned by insiders.

Analysts Set New Price Targets

Several research firms have weighed in on REGN. StockNews.com began coverage on Regeneron Pharmaceuticals in a research note on Wednesday, October 12th. They set a “hold” rating on the stock. Piper Sandler lowered their price target on Regeneron Pharmaceuticals from $775.00 to $765.00 and set an “overweight” rating for the company in a research note on Thursday, November 3rd. The Goldman Sachs Group boosted their price target on Regeneron Pharmaceuticals from $796.00 to $970.00 and gave the company a “buy” rating in a research note on Monday, October 3rd. Cowen boosted their price target on Regeneron Pharmaceuticals from $655.00 to $750.00 in a research note on Thursday, October 20th. Finally, EF Hutton Acquisition Co. I reissued a “buy” rating and issued a $851.00 price target on shares of Regeneron Pharmaceuticals in a research note on Wednesday, January 11th. One analyst has rated the stock with a sell rating, six have given a hold rating and fourteen have given a buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $786.15.

Regeneron Pharmaceuticals Company Profile

(Get Rating)

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.

See Also

Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGNGet Rating).

Institutional Ownership by Quarter for Regeneron Pharmaceuticals (NASDAQ:REGN)

Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.